Drug Discovery
Antibody Therapeutics
Identifying Antibodies for
Therapeutic Use
Adaptive’s high-throughput antibody discovery process enables rapid identification and selection of potent, naturally occurring, entirely human antibodies for clinical development and commercialization.
![Two-tone-icon–Versatility-](https://adaptivebiotech.com/wp-content/uploads/2023/05/Two-tone-icon-Versatility-q49lps8mdapoa9azbt1fdmn5hx0bhv28yoz8pl5gyq.webp)
Versatility
- Use B cells from human blood
- Sourced from humanized mice
![Two-tone-icon–Safety-01](https://adaptivebiotech.com/wp-content/uploads/2023/05/Two-tone-icon-Safety-01-q49lps8mdapoa9azbt1fdmn5hx0bhv28yoz8pl5gyq.webp)
Safety
- De-risked for manufacturing and developability
- Likely favorable safety profile
![Two-tone-icon–Selection](https://adaptivebiotech.com/wp-content/uploads/2023/05/Two-tone-icon-Selection-q49lps8mdapoa9azbt1fdmn5hx0bhv28yoz8pl5gyq.webp)
High-throughput, high sensitivity
- Hundreds of thousands of antibodies at a time
- Select likely winners using bioinformatics
- Accurate BCR heavy/light pairs at unprecedented scale
- Screen for natural human antibodies
![Two-tone-icon–T-Cell](https://adaptivebiotech.com/wp-content/uploads/2023/05/Two-tone-icon-T-Cell-q49lps8mdapoa9azbt1fdmn5hx0bhv28yoz8pl5gyq.webp)
Best clinical candidate selection
- Entire B-cell receptors (BCR) repertoire interrogated
- Well-characterized, naturally optimized antibodies
- Support rational monoclonal antibody combinations
Developing Therapeutic
Antibodies Against SARS-CoV-2
Neutralizing antibodies defend healthy cells by blocking the biological function of an invading virus.
Adaptive has identified and characterized ultra-potent, neutralizing antibodies that bind to different parts of the SARS-CoV-2 virus and can be considered for development to treat COVID-19.
View Publications for the article published in Cell Chemical Biology in 2023.